Biochemical Confirmation of Anti-Inflammatory Activity of Oxicam-Based Pharmaceutical Compositions

Yıl 2018, Cilt: 5 Sayı: 3, 1407 - 1412, 01.09.2018

Ganna Syrova Tetyana Tishakova Olga Levashova Olena Savelieva

https://doi.org/10.18596/jotcsa.463663

Cited By: 1

Öz

Biochemical
confirmation of anti-inflammatory activity of oxicam-based pharmaceutical
compositions was performed by the determination of the level of one of the main
markers of inflammation-C-reactive protein. Biochemical studies were carried
out on laboratory animals (white WAG rats) to study the anti-inflammatory
effects of meloxicam, piroxicam, caffeine, and
pharmaceutical compositions consisting of meloxicam and caffeine, piroxicam and
caffeine compared to the reference drug - sodium diclofenac. The content of CRP
in serum of rats was determined using the CRP latex test kit (State
registration number 1248/2002, Kharkiv, Ukraine). It was shown that composition of meloxicam and caffeine reduced the
content of CRP by 16 times compared with formalin-induced
edema, and by 2 times in comparison with the reference drug diclofenac sodium, which is statistically
significantly different from the control, i.e. caffeine increases and potentiates anti-inflammatory action of
meloxicam.

Anahtar Kelimeler

anti-inflammatory activity, parmaceutical composition

Kaynakça

• 1. Isakov VA. Gastropathy associated with the use of non-steroidal anti-inflammatory drugs pathogenesis, treatment, prevention. Clinical Pharmacology & Therapeutics . 2005; 14(2): 34—8. [in Russian]
• 2. Nasonov EL, Nasonova VA. The pharmacotherapy of pain: rheumatologist's glance. Consilium medicum. 2000; 2(12):509-14. [in Russian]
• 3. Scherbenkov IM. Problems of perioperative anaesthesis. Consilium Medicum. 2011; 8: 78-81. [in Russian]
• 4. Nasonov EL, Zvetkova ES, Balabanova RM. New aspects of anti-inflammatory therapy of rheumatic diseases: theoretical background and clinical application of meloxicam. Сlinical medicine. 2006; 4: 4-8. [in Russian]
• 5. Nakonechna SA, Honcharenko MM, Aleksieieva TM. Experimental study of antipyretic effect of paracetamol composition with caffeine. Experimental and clinical medicine. 2015; 1(66): 47-9. [in Ukrainian]
• 6. Dix P, Prosser DP, Streete P. A pharmacokinetic study of piroxicam in children. Anaesthesia. 2004; 59:984-7.
• 7. Abdallah FI, Dawaba HM, Mansour A et al. Evaluation of the anti-inflammatory and analgesic effects of piroxicamloaded microemulsion in topical formulations. International Journal of Pharmacy and Pharmaceutical Sciences. 2011; 3(2):66-70.
• 8. Boiko Ye. P., Lymanska G.O., Petunin P.O., Bachinskyi R.O. Study of the effect of caffeine composition with ibuprofen on the central component of nociceptive response in rats. Contemporary theoretical and practical aspects of clinical medicine: materials of the international conference of students and young scientists devoted to the 155th anniversary of V.V. Podvysotsky's birth. Odesa. 2012; 116. [in Ukrainian]
• 9. Syrova GO, Zvyagintseva TV, Chekman IS et al. Quantum-pharmacological substantiation of potentiating anticoagulant properties of caffeine. Pharm. Journal. 2008; 6:85-91. [in Ukrainian]
• 10. Syrova GO, Zvyagintseva TV. Study of potentiating anticoagulant properties of caffeine in an experiment. Congress of the World Federation of Ukrainian Medical Associations: book of abstracts. Ivano-Frankivsk. 2008; 454. [in Ukrainian]
• 11. Boiko I, Syrova G, Ermolenko T. Experimental conformation of the caffeine’s potentiation of the analgetic properties. 3th International Scientific interdisciplinary Congress of medical students and young doctors. Kharkiv. 2010; 14. [in Russian]
• 12. Ghelardini С, Galeotti N, Bartolini A. Caffeine induces central cholinergic analgesia. Naunyn Schmiedebergs Arch Pharmacol. 1997; 356(5):590-5. 13. Karelov AE, Zaychik AM, Lebedinskiy KM. Purine analgesia: From Theory to Practical Implementation. Proceedings of the III Congress of pharmacologists of Russia, St. Petersburg. 2007; 7(1): 1718 [in Russian].
• 14. Mazon SB, Monte AS, Almeida EA, Guariento ME. Determining the C-Reactive Protein Level in Patients With Different Clinical Forms of Chagas Disease. Rev Esp Cardiol. 2010; 63(9):1096−9.
• 15. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003; 111(12):1805–12.
• 16. Syrova GО, Levashova OL, Tishakova TS, Kozub SN, Chalenko NN. Investigation of quantum-chemical properties of indomethacin. The scientific heritage. 2017; 16(16):11-16.
• 17. Preclinical studies of drugs. Methodological recommendations edited by O.V. Stefanova. Kyiv, 2001; 527. [in Ukrainian]